Aclaris Therapeutics - 9 Asse im Ärmel!
Seite 1 von 5
neuester Beitrag: 22.07.20 17:49
|eröffnet am:||03.05.19 12:25 von:||moneywork4.||Anzahl Beiträge:||123|
|neuester Beitrag:||22.07.20 17:49 von:||Balu4u||Leser gesamt:||13949|
|bewertet mit 1 Stern
moneywork4me : Aclaris Therapeutics - 9 Asse im Ärmel!
Kursziele bis 50 USD (Kurs aktuell: 6,06 USD)
April 26, 2019 Healthcare, Top Market News 0 Comments
Cantor Fitzgerald Remains a Buy on Aclaris Therapeutics Inc (ACRS)
By Carrie Williams
[Cantor Fitzgerald Remains a Buy on Aclaris Therapeutics Inc (ACRS)] In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Aclaris Therapeutics Inc (ACRS ? Research Report), with a price target of $50. The company?s shares closed yesterday at $6.83, close to its 52-week low of $5.04.
?We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of 50 USD.
Vassago : ACRS 1.37$
Zahlen für 2019
- Umsatz 4 Mio. $
- Verlust 161 Mio. $
- Cash 75 Mio. $
- MK 57 Mio. $
"Aclaris anticipates that its cash, cash equivalents and marketable securities as of December 31, 2019, will be sufficient to fund its operations into the third quarter of 2021, without giving effect to any potential business development transactions or financing activities."
Vassago : ACRS 2.78$ (vorbörslich +88%)
ATI-450 darf bei COVID-19 Patienten getestet werden
Zahlen für Q1/20
- Umsatz 1,4 Mio. $
- Verlust 15,6 Mio. $
- Cash 79 Mio. $
- MK 62 Mio. $ (auf Basis des Schlusskurses von gestern bei 1.48$)
Kleine_prinz : super news..
Kleine_prinz : Bald müssen auch darüber news kommen..
Kleine_prinz : Infos zu Aclaris ATI-450
Jun. 17, 2020, 01:35 PM
(RTTNews) - Clinical-stage biopharmaceutical company Aclaris Therapeutics, Inc. (ACRS) announced Wednesday that the U.S. Food and Drug Administration (FDA) has allowed an investigational new drug (IND) application to evaluate ATI-450, its oral investigational MK2 inhibitor compound, in hospitalized patients with COVID-19.
Aclaris is supporting an investigator-initiated trial of ATI-450 for cytokine release syndrome (CRS) in 36 hospitalized patients with COVID-19, and will provide funding and clinical drug supply to the University of Kansas Medical Center (KUMC), the sponsor of the trial.
Balu4u : Ja, endlich mal wieder ein Lebenszeichen
Balu4u : Die ganzen Gewinne wieder dahin...
Kleine_prinz : Gute News Aclaris Therapeutics
WAYNE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that it has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, for the treatment of moderate to severe atopic dermatitis (AD). ATI-1777 is another compound generated from the Aclaris KINect™ drug discovery platform, and was specifically developed as a topical “soft” drug.
Kleine_prinz : Bald müsste es news darüber geben..
If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
Kleine_prinz : Interessant..
New Drug for COVID-19 Treatment is Developed in St. Louis with Clinical Trial in Kansas
Aclaris is supporting an investigator-initiated trial of ATI-450 in 36 hospitalized patients with COVID-19, and will provide funding and the clinical drug supply to the University of Kansas Medical Center (KUMC), the sponsor of the trial located in Kansas City, Kansas.
The clinical trial is underway to treat patients with the novel coronavirus because COVID-19 can cause acute respiratory distress syndrome, ARDS.
“Literature that’s come out over the last four or five months suggests one of the causes of ARDS is a hyperactive immune response, so the immune system is triggered when you get the viral infection, but for some reason the immune system goes a little haywire and this results in an inflammatory state,” explained Monahan. “The data suggests that this inflammatory state, this hyperinflammation, is associated with an upregulation of certain proteins that come from both diseased tissue and immune cells, called cytokines. And these cytokines could be the culprit in driving this ARDS and the inflammation seen in the lung in COVID-19 patients.”
Monahan explained the reason it’s believed ATI-450 will work as a rheumatoid arthritis treatment is because the drug downregulates cytokines, inhibiting their production.